Prof Wassilios Meissner

MD PhD

Visiting Professor

New Zealand Brain Research Institute, Christchurch

I am a Neurologist, with subspecialty expertise in Movement Disorders and particular interest in Parkinson’s disease (PD) and atypical parkinsonian disorders such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). I am currently on a research leave at the NZBRI and have a visiting appointment at the University of Otago. The main goal of my research leave is to learn more about eye movement control in healthy subjects and patients with parkinsonian disorders.

My main affiliation is with the University of Bordeaux in France where I am Professor of Neurology since 2012. Within my clinical activities, I am director of the PD Expert Centre Bordeaux and co-chair of the French Reference Centre for MSA.

My current research focuses on biological and clinical markers of disease progression in PD and MSA, as well as the development of new preclinical models and treatments for PD and MSA in a translational approach. Within my current research activities, I have recently completed a phase 1 study with two innovative vaccines directed against alpha-synuclein in patients with MSA (http://sympath-project.eu) and coordinate the European ARTEMIS consortium (http://www.erare.eu/financed-projects/artemis).

Publications

Provided on request for non-commercial personal use by researchers.

2021

Kalampokini, S., Hommel, A. L., Lorenzl, S., Ferreira, J. J., Meissner, W. G., Odin, P., Bloem, B. R., Dodel, R., Schrag, A. E. (2021). Caregiver burden in late-stage parkinsonism and its associations. Journal of Geriatric Psychiatry and Neurology. 10.1177/0891988720968263

2020

Adrianus, L., Meinders, M., Weerkamp, N., Richinger, C., Schmotz, C., Lorenzl, S., Dodel, R., Coelho, M., Ferreira, J., Tison, F., Boraud, T., Meissner, W. G., Rosqvist, K., Timpka, J., Odin, P., Wittenberg, M., Bloem, B., Koopmans, R., Schrag, A. (2020). Optimizing treatment in undertreated late-stage parkinsonism: a pragmatic randomized trial. Journal of Parkinson’s Disease, 10, 1171-1184. 10.3233/JPD-202033
Grimm, M. J., Respondek, G., Stamelou, M., Arzberger, T., Ferguson, L., Gelpi, E., Giese, A., Grossman, M., Irwin, D., Pantelyat, A., Rajput, A., Roeber, S., van Swieten, J., Troakes, C., Meissner, W. G., Nilsson, C., Piot, I., Compta, Y., Rowe, J., Höglinger, G. (2020). Clinical conditions “Suggestive of Progressive Supranuclear Palsy” — diagnostic performance. Movement Disorders, 35, 2301-2313. 10.1002/mds.28263
Hommel, A. L., Meinders, M. J., Lorenzl, S., Dodel, R., Coelho, M., Ferreira, J. J., Laurens, B., Spampinato, U., Meissner, W. G., Rosqvist, K., Timpka, J., Odin, P., Wittenberg, M., Bloem, B., Koopmans, R., Schrag, A., Care of Late‐Stage Parkinsonism Consortium. (2020). The prevalence and determinants of neuropsychiatric symptoms in late‐stage parkinsonism. Movement Disorders Clinical Practice, 7, 531-542. 10.1002/mdc3.12968
Hommel, A. L., Meinders, M. J., Weerkamp, N. J., Richinger, C., Schmotz, C., Lorenzl, S., Dodel, R., Coelho, M., Ferreira, J., Tison, F, Boraud, T., Meissner, W. G., Rosqvist, K., Timpka, J., Odin, P., Wittenberg, M., Bloem, B., Koopmans, R., Schrag, A. (2020). Optimizing treatment in undertreated late-stage parkinsonism: a pragmatic randomized trial. Journal of Parkinson's disease,  . 10.3233/JPD-202033
Lopez‐Cuina, M., Guerin, P. A., Canron, M. H., Delamarre, A., Dehay, B., Bezard, E., Meissner, W. G., Fernagut, P. O. (2020). Nilotinib fails to prevent synucleinopathy and cell loss in a mouse model of multiple system atrophy. Movement Disorders, 35, 1163-1172. 10.1002/mds.28034
Markaki, I., Bergström, S., Tsitsi, P., Remnestål, J., Månberg, A., Hertz, E., Paslawski, W., Sorjonen, K., Uhlén, M., Mangone, G., Carvalho, S., Rascol, O., Meissner, W. G., Magnin, E., Wüllner, U., Corvol, J., Nilsson, P., Svenningsson, P. (2020). Cerebrospinal fluid levels of Kininogen‐1 indicate early cognitive impairment in Parkinson's disease. Movement Disorders, 35, 2101-2106. 10.1002/mds.28192
Meissner, W. G., Traon, A. P. L., Foubert‐Samier, A., Galabova, G., Galitzky, M., Kutzelnigg, A., ... , Rascol, O. (2020). A Phase 1 randomized trial of specific active α‐synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Movement Disorders, 35, 1957-1965. 10.1002/mds.28218
Painous, C., van Os, N. J. H., Delamarre, A., Michailoviene, I., Marti, M. J., van de Warrenburg, B. P., Meissner, W. G., …, Tijssen, M. A. (2020). Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases. European Journal of Neurology, 27, 1493-1500. 10.1111/ene.14302
Phokaewvarangkul, O., Vorachit, S., Phoumindr, A., Keosodsay, S., Postuma, R. B., Meissner, W. G., Bhidayasiri, R. (2020). Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic. BMC Medical Education, 20, 1-7. 10.1186/s12909-020-02161-x
Rascol, O., Negre-Pages, L., Damier, P., Delval, A., Derkinderen, P., Destée, A., Fabbri, M., Meissner, W.G., Rachdi, A., Tison, F. and Perez-Lloret, S. (2020). Utilization patterns of amantadine in Parkinson’s disease patients enrolled in the French COPARK study. Drugs & Aging, 37, 215-223. 10.1007/s40266-019-00740-2
Download Validation of the Movement Disorder Society criteria for the diagnosis of 4‐repeat tauopathies.
Respondek, G., Grimm, M. J., Piot, I., Arzberger, T., Compta, Y., Englund, E., Ferguson, L., Gelpi, E., Roeber, S., Giese, A., Grossman, M., Irwin, D., Meissner, W. G., Nilsson, C., Pantelyat, A., Rajput, A., van Swieten, J., Troakes, C., Höglinger, G., Whitwell, J. L. (2020). Validation of the Movement Disorder Society criteria for the diagnosis of 4‐repeat tauopathies. Movement Disorders, 35, 171-176. 10.1002/mds.27872
Yu, Z., Shi, M., Stewart, T., Fernagut, P. O., Huang, Y., Tian, C., …, Meissner, W.G., Zhang, J. (2020). Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain, 143, 1780-1797. 10.1093/brain/awaa110

2019

Download Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease.
Delamarre, A., Tison, F., Li, Q., Galitzky, M., Rascol, O., Bezard, E., Meissner, W. G. (2019). Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease. Journal of Neural Transmission, 126, 789-793. 10.1007/s00702-019-02015-x
Grimm, M. J., Respondek, G., Stamelou, M., Arzberger, T., Ferguson, L., Gelpi, E., Giese, A., Grossman, M., Irwin, D. J., Pantelyat, A., Rajput, A., Roeber, S., van Swieten, J. C., Troakes, C., Antonini, A., Bhatia, K. P., Colosimo, C., van Eimeren, T., Kassubek, J., Levin, J., Meissner, W. G., Nilsson, C., Oertel, W. H., Piot, I., Poewe, W., Wenning, G. K., Boxer, A., Golbe, L. I., Josephs, K. A., Litvan, I., Morris, H. R., Whitwell, J. L., Compta, Y., Corvol, J. C., Lang, A. E., Rowe, J. B., Höglinger, G. U., Movement Disorder Society-endorsed PSP Study Group (2019). How to apply the Movement Disorder Society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders. 10.1002/mds.27666
Vergnet, S., Hives, F., Foubert-Samier, A., Payoux, P., Fernandez, P., Meyer, M., ..., Meissner, W. G. (2019). Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism & Related Disorders. 10.1016/j.parkreldis.2019.02.006

Abstracts and Short papers

2020

Delamarre, A., Rigalleau, V., Meissner, W. G. (2020). Insulin resistance, diabetes and Parkinson’s disease: the match continues. Parkinson’s and Related Disorders, 80, 199-200. 10.1016/j.parkreldis.2020.10.013
Meissner, W. G., Höglinger, G. U. (2020). Looking into the prediagnostic phase of progressive supranuclear palsy. Parkinsonism and Related Disorders, 74. 10.1016/j.parkreldis.2020.04.006